JB Chemicals & Pharmaceuticals Ltd.
http://www.jbcpl.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From JB Chemicals & Pharmaceuticals Ltd.
Torrent On Acquisition And Licensing Strategy, Vonoprazan Trajectory
Amid deals activity in India, Torrent Pharma executives spelt out their acquisition expectations and licensing strategy while an in-licensed Takeda brand did well in Q1 of FY25. The US growth trajectory is seen determined by five to ten product approvals expected this fiscal
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
Stake Sale Speculation At Two PE-Controlled Firms In India: Will Valuations Fly?
Two top-50 Indian firms are speculated to be on the block with valuations expected to be richer than past multiples paid by buyers. A small, less known life sciences solutions provider is also keen to rope in a CDMO partner. Scrip speaks to a cross-section of experts on the action in deal street.
Podcast: Amid Talk Of KKR Stake Sale, JB CEO Stresses Business As Usual
In an interview with JB CEO Nikhil Chopra, Scrip discusses talk of a stake sale by private equity fund KKR, gains from acquisitions including select Novartis brands, plans to ascend to the top five in cardiology and a ramp up of the CDMO business, which has clients including J&J.
Company Information
- Industry
- Pharmaceuticals
- Contract Manufacturing Organization
- Other Names / Subsidiaries
-
- Unique Pharmaceutical Laboratories
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice